Legal & General Group
OREX

Legal & General Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Legal & General Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,785
Closed -$10K – 3001
2016
Q1 		$10K Hold
1,785
– – ﹤0.01% 2745
2015
Q4 		$33K Hold
1,785
– – ﹤0.01% 2619
2015
Q3 		$38K Hold
1,785
– – ﹤0.01% 2587
2015
Q2 		$84K Hold
1,785
– – ﹤0.01% 2250
2015
Q1 		$138K Hold
1,785
– – ﹤0.01% 1847
2014
Q4 		$107K Hold
1,785
– – ﹤0.01% 1926
2014
Q3 		$78K Buy
+1,785
New +$95.9K ﹤0.01% 2093

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Legal & General Group's OREX Position: Q2 2016 in Review

Legal & General Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 1,785 shares — an estimated $10K sold.

Legal & General Group first reported a position in OREX in Q3 2014 and held it in 7 quarters. The position peaked at $138K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Legal & General Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Legal & General Group sold 1,785 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $10K.
  • Legal & General Group first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 7 quarters.
  • Legal & General Group's Orexigen Therapeutics, Inc. position peaked at $138K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Legal & General Group's 13F filing for Q2 2016, filed 16 Aug 2016.